Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Alteration of the SETBP1 Gene and Splicing Pathway Genes SF3B1, U2AF1, and SRSF2 in Childhood Acute Myeloid Leukemia

  • Choi, Hyun-Woo (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital) ;
  • Kim, Hye-Ran (Brain Korea 21 Plus Project, Chonnam National University Medical School) ;
  • Baek, Hee-Jo (Department of Pediatrics, Chonnam National University Hwasun Hospital) ;
  • Kook, Hoon (Department of Pediatrics, Chonnam National University Hwasun Hospital) ;
  • Cho, Duck (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital) ;
  • Shin, Jong-Hee (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital) ;
  • Suh, Soon-Pal (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital) ;
  • Ryang, Dong-Wook (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital) ;
  • Shin, Myung-Geun (Department of Laboratory Medicine, Chonnam National University Hwasun Hospital)
  • Received : 2014.03.24
  • Accepted : 2014.09.25
  • Published : 2015.01.02
⟨ Previous Next ⟩

Abstract

Background: Recurrent somatic SET-binding protein 1 (SETBP1) and splicing pathway gene mutations have recently been found in atypical chronic myeloid leukemia and other hematologic malignancies. These mutations have been comprehensively analyzed in adult AML, but not in childhood AML. We investigated possible alteration of the SETBP1, splicing factor 3B subunit 1 (SF3B1), U2 small nuclear RNA auxiliary factor 1 (U2AF1), and serine/arginine-rich splicing factor 2 (SRSF2) genes in childhood AML. Methods: Cytogenetic and molecular analyses were performed to reveal chromosomal and genetic alterations. Sequence alterations in the SETBP1, SF3B1, U2AF1, and SRSF2 genes were examined by using direct sequencing in a cohort of 53 childhood AML patients. Results: Childhood AML patients did not harbor any recurrent SETBP1 gene mutations, although our study did identify a synonymous mutation in one patient. None of the previously reported aberrations in the mutational hotspot of SF3B1, U2AF1, and SRSF2 were identified in any of the 53 patients. Conclusions: Alterations of the SETBP1 gene or SF3B1, U2AF1, and SRSF2 genes are not common genetic events in childhood AML, implying that the mutations are unlikely to exert a driver effect in myeloid leukemogenesis during childhood.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M, et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010;42:483-5. https://doi.org/10.1038/ng.581
  2. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:18-24. https://doi.org/10.1038/ng.2495
  3. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013;27:1401-3. https://doi.org/10.1038/leu.2013.35
  4. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, Abe T, Copeland TD, Ueda K, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem 2001;268:1340-51. https://doi.org/10.1046/j.1432-1327.2001.02000.x
  5. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010;115:615-25. https://doi.org/10.1182/blood-2009-06-227363
  6. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9. https://doi.org/10.1038/nature10496
  7. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013;27:2072-5. https://doi.org/10.1038/leu.2013.145
  8. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120:3187-205. https://doi.org/10.1182/blood-2012-03-362608
  9. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012;119:3203-10. https://doi.org/10.1182/blood-2011-12-399774
  10. Choi HJ, Kim HR, Shin MG, Kook H, Kim HJ, Shin JH, et al. Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems. J Korean Med Sci 2011;26:886-92. https://doi.org/10.3346/jkms.2011.26.7.886
  11. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer 2012;12:304. https://doi.org/10.1186/1471-2407-12-304
  12. Liang DC, Liu HC, Yang CP, Jaing TH, Hung IJ, Yeh TC, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood 2013;121:2988-95. https://doi.org/10.1182/blood-2012-06-436782
  13. Shiba N, Ohki K, Park MJ, Sotomatsu M, Kudo K, Ito E, et al. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Br J Haematol 2014;164:142-59. https://doi.org/10.1111/bjh.12559
  14. Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer 2013;133:260-5. https://doi.org/10.1002/ijc.28011
  15. Kar SA, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 2013;98:107-13. https://doi.org/10.3324/haematol.2012.064048
  16. Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C. Silent (synonymous) SNPs: should we care about them? Methods MolBiol 2009;578:23-39.
  17. Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet 2006;7:98-108. https://doi.org/10.1038/nrg1770
  18. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-riskpediatric acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol 2011;29:704-11. https://doi.org/10.1200/JCO.2010.31.9327
  19. Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Gohring G, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010;28:578-85. https://doi.org/10.1200/JCO.2009.23.0342
  20. Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG. Blood 2011;118:4561-6. https://doi.org/10.1182/blood-2011-04-348888
  21. National Center for Biotechnology Information, U.S. National Library of Medicine, SNP database. http://www.ncbi.nlm.nih.gov/SNP/index.html (Updated on Oct 2013).

Cited by

  1. Somatic SETBP1 mutations in myeloid neoplasms vol.105, pp.6, 2015, https://doi.org/10.1007/s12185-017-2241-1
  2. Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis vol.15, pp.1, 2015, https://doi.org/10.1016/j.gpb.2016.12.002
  3. SETBP1 dysregulation in congenital disorders and myeloid neoplasms vol.8, pp.31, 2015, https://doi.org/10.18632/oncotarget.17231
  4. Next‐generation sequencing identifies novel single nucleotide polymorphisms in high‐risk cutaneous squamous cell carcinoma: A pilot study vol.29, pp.7, 2020, https://doi.org/10.1111/exd.14120
  5. SF3A1 Gene Polymorphism Affects Clinical Features, but not Susceptibility to Myelodysplastic Syndromes vol.70, pp.4, 2015, https://doi.org/10.2974/kmj.70.315